Last update Oct. 5, 2023

Co-dergocrine Mesilate, codergocrine

Incompatible

Very unsafe. Contraindicated. Use of an alternative or cessation of breastfeeding. Read the Commentary.

It is a mixture of hydrogenated ergot alkaloids used as an adjunct in the symptomatic treatment of mild to moderate dementia in the elderly. It is also used in the treatment of hypertension, migraine and peripheral vascular disease. Oral administration in three daily doses. Also sublingually, intramuscularly, subcutaneously or by intravenous infusion.

At the date of the last update we did not find published data on its excretion in breast milk.

Its pharmacokinetic data (very large volume of distribution and moderately high molecular weight) make it unlikely to pass into breast milk in clinically significant quantities.

Like all ergot derivatives, it is a dopaminergic agonist and therefore reduces prolactin secretion (Dominiak 1988) and may suppress lactation.


See below the information of this related product:

  • Ergot Fungus (Very unsafe. Contraindicated. Use of an alternative or cessation of breastfeeding. Read the Commentary.)

Alternatives

We do not have alternatives for Co-dergocrine Mesilate, codergocrine.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Co-dergocrine Mesilate, codergocrine is also known as


Co-dergocrine Mesilate, codergocrine in other languages or writings:

Group

Co-dergocrine Mesilate, codergocrine belongs to this group or family:

Tradenames

Main tradenames from several countries containing Co-dergocrine Mesilate, codergocrine in its composition:

List of 10 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 2.25 ± 0.65 %
Molecular weight 660 daltons
Protein Binding 81 %
VD 2 l/Kg
Tmax 1 hours
T½ 7.5 ± 1.2 hours

References

  1. [No authors listed] Do not use drugs to prevent onset of lactation. Relieve the discomfort and wait. Prescrire Int. 2013 Abstract
  2. Setnikar I, Schmid K, Rovati LC, Vens-Cappell B, Mazur D, Kozak I. Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation. Arzneimittelforschung. 2001 Jan;51(1):2-6. Abstract
  3. Dominiak P, Grevel J, Abisch E, Grobecker H, Dennler HJ, Welzel D. The absolute systemic availability of a new oral formulation of co-dergocrine in healthy subjects. Eur J Clin Pharmacol. 1988;35(1):53-7. Abstract

Total visits

4,071

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM